¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-22
±³À°ÀÏÀÚ : 2024-06-22
±³À°Àå¼Ò : ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ ÄÁº¥¼ÇȦ4F

±³À°ÁÖÁ¦ : 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ

´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520

À̸ÞÀÏ : retina@retina.or.kr

±³À°Á¾·ù : ¾È°ú

Âü¼®¿¹»óÀÎ : 170¸í
Èñ¸ÁÆòÁ¡ : 1Á¡

Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 1 ½Ã°£ 36ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:00~09:08 (ÃÊ·Ï)Asian Subgroup Analysis of a Phase III Study Comparing SB15 with Reference Aflibercept (Eylea) in Neovascular Age-related Macular Degeneration ÀÌÁÖ¿ë(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:08~09:16 (ÃÊ·Ï)Real-world incidence and risk factors of incident non-infectious uveitis in patients treated with Immune checkpoint inhibitors ±è¿ëÁØ(¿¬¼¼´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:16~09:24 (ÃÊ·Ï)Progression of myopia and related structural changes in retina: school-based prospective cohort study ¹è°ÇÈ£(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:24~09:32 (ÃÊ·Ï)Cost-effectiveness of the anti-vascular endothelial growth factor intravitreal injection and panretinal photocoagulation for patients with proliferative diabetic retinopathy in South Korea Áöµ¿Çö(°¡Å縯´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:32~09:40 (ÃÊ·Ï)Case series of branch retinal vein occlusion secondary to rhegmatogenous retinal detachment and its surgical management ¹Ú¼ºÈÄ(ºÎ»ê´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:40~09:48 (ÃÊ·Ï)Prevalence and Risk Factors of Age-related Macular Degeneration in South Korea: Korea National Health and Nutrition Examination Survey 2017-2020 ±èÀçÈÖ(±è¾È°úº´¿ø)

ÈÞ½Ä 06¿ù 22ÀÏ 09:48~09:55 ÈÞ½Ä -(-)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 09:55~10:03 (ÃÊ·Ï)Introducing New Retinal Vessel Analysis Software: SEoul Retinal Vessel Assessment Library (SERVAL) ¹Ú»óÁØ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 10:03~10:11 (ÃÊ·Ï)Multimodal deep learning-based prediction of treatment response in diabetic macular edema À±Á¦¹®(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 10:11~10:19 (ÃÊ·Ï)A novel fluorescent diagnostic agent targeting choroidal neovascularization Ãֽ¿ì(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 10:19~10:27 (ÃÊ·Ï)Epiretinal Membrane: Exploring Correlations between Clinical and immunohistochemical Characteristics and Their Prognostic Implications ¾çÇö½Â(¼­¿ï½Å¼¼°è¾È°ú)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 10:27~10:35 (ÃÊ·Ï)Changes in the outer nuclear layer and choroidal vascularity during the manifest and quiescent phases of acute central serous chorioretinopathy ¼­ÀÇÁ¾(ÃæºÏ´ë)

±³À°½Ã°£ 06¿ù 22ÀÏ 4F ÄÁº¥¼ÇȦ 10:35~10:43 (ÃÊ·Ï)Macular microvasculature asymmetry in high myopia patients with open-angle glaucoma À̹οì(°Ç¾ç´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) Á¦7ȸ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ¾îÁö·³Áõ¼¾ÅÍ ¿¬¼ö°­Á : 2024-06-22
´ÙÀ½±Û ´ëÇÑÃé´ãµµÇÐȸ [¿Â¶óÀÎ] Pancreato-Biliary Summer School 2024 (PB-SS) : 2024-06-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
272 ¼­¿ï Çѱ¹ºÐÀÚ¼¼Æ÷»ý¹°ÇÐȸ Á¤±âÇмú´ëȸ : 2018-09-17 0 449 2018-07-28
271 °æ±â Á¦ 1ȸ ¾ÆÁִ뺴¿ø ½ÅÀå³»°ú ¿¬¼ö°­Á : 2018-09-16 0 2,165 2018-07-28
270 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Á¦53Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2018-09-16 0 607 2018-07-28
269 ¼­¿ï 2018³â Á¦3ȸ »ï¼º¼­¿ïº´¿ø ¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-09-16 0 951 2018-07-28
268 ´ë±¸ 2018³âµµ ´ëÇÑÁ¤Çü¿Ü°úÀÇ»çȸ Çмú´ëȸ : 2018-09-16 0 851 2018-07-28
267 ¼­¿ï ½ÉÀå´ë»çÁõÈıº¿¬±¸È¸ 2018 Ãß°è½ÉÆ÷Áö¾ö : 2018-09-15 0 692 2018-07-28
266 ¼­¿ï °æÈñ´ëÇб³º´¿ø µ¿¹®Áý´ãȸ_°íȲÀ̺ñÀÎÈÄ°ú ¿¬±¸È¸ ¼¼¹Ì³ª : 2018-09-15 0 1,446 2018-07-28
265 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : °æ°è¼± ÀΰÝÀå¾Ö : 2018-09-15 0 1,231 2018-07-28
264 ¼­¿ï ¼­¿ï¼º¸ðº´¿ø ½ÅÀåÀÌ½Ä 3,000·Ê ±â³ä ´ëÇÑÀ̽ÄÇÐȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2018-09-15 0 672 2018-07-28
263 °­¿ø ´ëÇÑ°ñÀýÇÐȸ Á¦2ȸ ÇÏÁö°ñÀý ½ÉÆ÷Áö¾ö : 2018-09-15 0 646 2018-07-28
262 Àü³² ¸ñÆ÷½ÃÀÇ»çȸ Çмú´ëȸ(°æµ¿¸Æ¼Õ»ó,°áÇÙ) : 2018-09-15 0 2,721 2018-07-28
261 ¼­¿ï °í·Á´ëÇб³ ½Å°æ°úÇб³½Ç ½ÉÆ÷Áö¿ò : 2018-09-15 0 1,978 2018-07-28
260 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø ÄÚºí·¹ÀÌÅ͸¦ ÀÌ¿ëÇÑ ´Ù¾çÇÑ ºñ°ú ¼ö¼úµé : 2018-09-15 0 773 2018-07-28
259 °æ±â Á¦6ȸ ÇѸ²´ëÇб³¼º½Éº´¿ø Á¤Çü¿Ü°ú °³¿øÀÇ ½ÉÆ÷Áö¿ò : 2018-09-15 0 909 2018-07-28
258 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª : 2018-09-14 0 655 2018-07-28
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷